» Articles » PMID: 20163421

1,24-Dihydroxyvitamin D₃ (tacalcitol) Prevents Skin T-cell Infiltration

Overview
Journal Br J Dermatol
Specialty Dermatology
Date 2010 Feb 19
PMID 20163421
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: 1,24-Dihydroxyvitamin D₃ (tacalcitol), a vitamin D(3) compound, has been used to treat T cell-mediated inflammatory skin diseases such as psoriasis, prurigo and vitiligo. The best-known mechanism of action of this compound is inhibition of the abnormal proliferation of keratinocytes and subsequent maturation; however, its effects on skin T-cell recruitment have not yet been evaluated. Cutaneous lymphocyte-associated antigen (CLA), a surface glycoprotein expressed on T cells, plays a critical role in skin T-cell infiltration. We recently reported that 1,25-dihydroxyvitamin D₃ inhibits skin infiltration of CD4+ T cells by suppressing CLA expression on T cells.

Objectives: In this study, we investigated the effect of tacalcitol on CLA epitope decoration and on the levels of gut or lymph node homing receptor expression in human T cells.

Methods: We cultured human T cells with tacalcitol and analysed the effect on CLA expression and skin-homing ability, and evaluated glycosyltransferase mRNAs. We also performed an in vivo study using an antigen-dependent delayed-type hypersensitivity (DTH) mouse model and investigated the effect of tacalcitol on skin-infiltrating CD4+ T cells.

Results: Tacalcitol downregulated the expression of CLA and, in parallel, the E- and P-selectin ligand function; however, it exerted no effect on other homing receptors. Subcutaneously and intraperitoneally administered tacalcitol downregulated skin infiltration of effector CD4+ T cells in an in vivo DTH mouse model.

Conclusions: These findings suggest that tacalcitol reduces skin inflammation by partially downregulating CLA expression levels.

Citing Articles

Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature.

Macedo R, Pasin C, Ganetsky A, Harle D, Wang X, Belay K Transplant Cell Ther. 2021; 28(1):18.e1-18.e10.

PMID: 34597852 PMC: 8792200. DOI: 10.1016/j.jtct.2021.09.017.


Clinical Characteristics of Japanese Patients with Palmoplantar Pustulosis.

Yamamoto T Clin Drug Investig. 2019; 39(3):241-252.

PMID: 30632109 DOI: 10.1007/s40261-018-00745-6.


Treatment of vitiligo vulgaris with the combination therapy of topical steroid and vitamin D3 compound.

Konishi Y, Yamanaka K, Mizutani H Dermatol Reports. 2014; 4(1):e8.

PMID: 25386318 PMC: 4212668. DOI: 10.4081/dr.2012.e8.


Tissue specific heterogeneity in effector immune cell response.

Tufail S, Badrealam K, Sherwani A, Gupta U, Owais M Front Immunol. 2013; 4:254.

PMID: 23986763 PMC: 3753596. DOI: 10.3389/fimmu.2013.00254.


Nonsegmental vitiligo and autoimmune mechanism.

Oiso N, Suzuki T, Fukai K, Katayama I, Kawada A Dermatol Res Pract. 2011; 2011:518090.

PMID: 21804820 PMC: 3144695. DOI: 10.1155/2011/518090.